GSK buys Sitari Pharmaceuticals a developer of a novel treatment for celiac disease.
Avalon Ventures announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI Pharmaceuticals, the Community of Innovation established by Avalon Ventures.
Sitari is developing a novel treatment for celiac disease, an autoimmune digestive disorder caused by intolerance to gluten, a protein found in wheat, rye and barley. Sitari's research is focused on inhibitors of transglutaminase 2 (TG2), which is responsible for the inflammatory cascade resulting from gluten exposure in patients with celiac disease. The TG2 inhibitors are still in preclinical development.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins